1-[2-(4-Aminopiperidin-1-yl)ethyl]-7-methoxy-1,4-dihydro-2H-3,1-benzoxazin-2-one trifluoro acetate → 1-[2-(4-Amino-2-oxopiperidin-1-yl)ethyl]-7-methoxy-3-methylquinazoline-2,4(1H,3H)-dione
반응식
C(OC(=O)[NH:7][CH:8]1[CH2:13][CH2:12][N:11]([CH2:14][CH2:15][N:16]2[C:25]3[C:20](=[CH:21][CH:22]=[C:23]([O:26][CH3:27])[CH:24]=3)[C:19](=[O:28])[N:18]([CH3:29])[C:17]2=[O:30])[CH2:10][CH2:9]1)(C)(C)C.FC(F)(F)C(O)=[O:35].NC1CCN(CCN2C3C=C(OC)C=CC=3COC2=O)CC1>>[NH2:7][CH:8]1[CH2:13][CH2:12][N:11]([CH2:14][CH2:15][N:16]2[C:25]3[C:20](=[CH:21][CH:22]=[C:23]([O:26][CH3:27])[CH:24]=3)[C:19](=[O:28])[N:18]([CH3:29])[C:17]2=[O:30])[C:10](=[O:35])[CH2:9]1참가 물질
3
반응물 2
생성물 1
실험 절차
tert-Butyl{1-[2-(7-methoxy-3-methyl-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)ethyl]piperidin-4-yl}carbamate (Intermediate 111, 350 mg, 0.83 mmol) was reacted as described for Intermediate 106. The crude trifluoro acetate of the title compound was obtained as a black oil, 395 mg (quantitative), and used without further purification for the next step.